Sun Pharma Advanced Research Company Ltd: Why Is It Outperforming Nifty 500?

Sun Pharma Advanced Research Company Ltd's latest quarterly results (Mar 2026) show

• PAT Growth YoY: +3035.0% (stable)
• Revenue Growth YoY: +6763.0%
• Operating Margin: 96.0% (volatile)

Sun Pharma Advanced Research Company Ltd's profit is growing with an stable trend.

• PAT Growth YoY: +3035.0% (latest quarter)
• PAT Growth QoQ: +2301.3% (sequential)
• 3-Year PAT CAGR: +11.4%
• Trend: Stable — consistent growth pattern

Sun Pharma Advanced Research Company Ltd's revenue growth trend is turning around (inflection up).

• Revenue Growth YoY: +6763.0%
• Revenue Growth QoQ: +23062.5% (sequential)
• 3-Year Revenue CAGR: +80.0%

Sun Pharma Advanced Research Company Ltd's operating margin is volatile.

• Current OPM: 96.0%
• OPM Change YoY: +292.0% basis points
• OPM Change QoQ: +766.0% basis points

Sun Pharma Advanced Research Company Ltd's long-term compounding rates

• 3-Year Profit CAGR: +11.4%
• 3-Year Revenue CAGR: +80.0%

Sun Pharma Advanced Research Company Ltd's earnings growth is stable with improving on a sequential basis.

• YoY Acceleration: +100.0% bps
• Sequential Acceleration: +55.3% bps

Sun Pharma Advanced Research Company Ltd's trailing twelve month (TTM) performance

• TTM PAT: ₹2,000 Cr
• TTM PAT Growth: +100.0% YoY
• TTM Revenue: ₹2,000 Cr
• TTM Revenue Growth: +100.0% YoY
• TTM Operating Margin: 85.4%

Sun Pharma Advanced Research Company Ltd appears significantly undervalued based on our fair value analysis.

• Valuation Signal: Significantly Undervalued
• Current PE: 4.7x
• Price-to-Book: 5.5x

Sun Pharma Advanced Research Company Ltd's current PE ratio is 4.7x.

• Current PE: 4.7x
• Market Cap: 7.3K Cr

Sun Pharma Advanced Research Company Ltd's current PE is 4.7x.

• Current PE: 4.7x
• Valuation Assessment: Significantly Undervalued

Sun Pharma Advanced Research Company Ltd's price-to-book ratio is 5.5x.

• Price-to-Book (P/B): 5.5x
• Book Value per Share: ₹41
• Current Price: ₹225

Sun Pharma Advanced Research Company Ltd is rated Strong with a fundamental score of 72/100. This score is calculated from objective financial metrics

• Revenue Growth YoY: +6763.0% (10% weight)
• PAT Growth YoY: +3035.0% (10% weight)
• PAT Growth QoQ: +2301.3% (10% weight)
• Margins stable (10% weight)

Sun Pharma Advanced Research Company Ltd has a debt-to-equity ratio of N/A.

• Total Debt: ₹559 Cr

Sun Pharma Advanced Research Company Ltd's return ratios over recent years

• FY2024: ROCE -108.0%
• FY2025: ROCE -279.0%
• FY2026: ROCE 164.0%

Sun Pharma Advanced Research Company Ltd's operating cash flow is negative (FY2026).

• Cash from Operations (CFO): ₹-239 Cr
• Free Cash Flow (FCF): ₹-263 Cr
• CFO/PAT Ratio: -15% (weak cash conversion)

Sun Pharma Advanced Research Company Ltd currently does not pay a significant dividend (yield 0.00%).

• Dividend Yield: 0.00%
• Current Price: ₹225

Sun Pharma Advanced Research Company Ltd's shareholding pattern (May 2026)

• Promoters: 65.7%
• FII (Foreign): 2.5%
• DII (Domestic): 0.1%
• Public: 31.8%

Sun Pharma Advanced Research Company Ltd's promoter holding has increased recently.

• Current Promoter Holding: 65.7% (May 2026)
• Previous Quarter: 65.7% (Mar 2026)
• Change: +0.01% (increasing — positive signal)

Sun Pharma Advanced Research Company Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.

Sun Pharma Advanced Research Company Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.

Based on quantitative research signals, here is why Sun Pharma Advanced Research Company Ltd may be worth studying

• Earnings growing at +3035.0% YoY
• Valuation: appears significantly undervalued

Sun Pharma Advanced Research Company Ltd investment thesis summary:

Sun Pharma Advanced Research Company Ltd's forward outlook based on current data signals

• Earnings Trend: stable
• Revenue Trend: turning around (inflection up)
• Margin Trend: volatile
• Valuation: Significantly Undervalued